US35104E1001
US35104E1001
4D Molecular Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 736.41M EUR | 734.35M EUR | 486.65M EUR | 432.06M EUR |
Enterprise Value | 379.48M EUR | 703.19M EUR | 434.7M EUR | 393.23M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -3.26x | -- | -- | -- |
Price to Sales | 8x | 7.98x | 5.51x | 5.07x |
Price to Book | 1.81x | 1.8x | 1.08x | 0.85x |
EV/Revenue | 4.12x | 7.64x | 4.93x | 4.62x |
EV/EBITDA | -2.01x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -12.33% | -21.24% | -26.58% | -14.17% |